Denmark: The new STENOCARE THC/CBD medical cannabis oil product is now available for sale in Denmark

Starting today the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot Programme. Out of the many suppliers seeking approval to …

Denmark: The new STENOCARE THC/CBD medical cannabis oil product is now available for sale in Denmark

Starting today the new product is available for sales to patients, and Stenocare is the only supplier of THC/CBD oil products under the Pilot Programme. Out of the many suppliers seeking approval to sell their products, Stenocare has been in a clear leadership position from the start of the Pilot in 2018 and is the only supplier of three different medical cannabis oil products under the Pilot.

Sales can begin: STENOCARE has successfully imported the first batch of a new medical cannabis oil product into Denmark. The new product is a combination THC/CBD oil containing 15 mg/ml THC and 24 mg/ml CBD with dosing delivered via an oral syringe. The new product is available starting today via pharmacies and requires a prescription.

Strong product portfolio: Stenocare is the first and so far, only supplier of this THC/CBD oil product for the Danish Pilot Programme. With this, Stenocare now once again has the complete portfolio of three medical cannabis oil products (ie. THC30 oil, CBD20 oil and now the THC/CBD oil). With this new product, Stenocare is able to offer the complete range of oil products they successfully sold to patients during 2018 and 2019, that grew the company sales and allowed the Company to reach breakeven in Q1 2019. Therefore, having this complete product range for the Danish Pilot Programme is an important element in the 2024 ambitions to once again reach breakeven at the end of the year.

Stenocare CEO Thomas Skovlund Schnegelsberg comments:

“Today we make yet another medical cannabis oil product available for patients. We now offer three different oil products, that together are addressing therapeutic needs across several illnesses. There are significant investments in regulatory work and documentation to have these products approved under the Danish Pilot Programme, and today’s milestone is another proof point for the unique skills and experiences of our regulatory team to meet the strict requirements of the Danish Medicines Agency. This fortifies Stenocare’s leading position in the Danish market.”

STENOCARE expands in Australia

Stenocare is a supplier of prescription-based medical cannabis oil products in several markets and has been present in the Australian market since Q4 2022. According to the National Drug Strategy Household Survey and Australian regulator report, the Australian medical …

STENOCARE expands in Australia

Stenocare is a supplier of prescription-based medical cannabis oil products in several markets and has been present in the Australian market since Q4 2022. According to the National Drug Strategy Household Survey and Australian regulator report, the Australian medical cannabis market size is approximately 450,000 patients (Dec-2023). The projected market growth rate is 15.77% CAGR from 2023 to 2028 with a forecasted market size US $791.60M by 2028 (Statista; Jul-2023). 

Under a new agreement, Stenocare has partnered with Quest Biotech Pharma ("QBP"), a highly specialized Australian pharmaceutical company. The shared objective is to expand the reach to more patients through qualified prescribing doctors. QBP partners with an holistic tele healthcare clinic - TeleDocs Clinic - serving patients with convenient access to medical care services nationwide from the Eastern States to Western Australia. This is a vast area with services open to all of Australia’s 26.6 million population. The mutual goal is to capture market share and achieve a 100% growth in the sales run rate of Stenocare-branded products in 2024.

Read the full announcement here: 2493725.pdf (cision.com)

GERMANY: STENOCARE is expanding outside Denmark with more prescription-based products.

Germany is the largest market in Europe with approx. 230.000 patients (out of 87 mill citizens) and projected sales of Euro 1 billion in 2027 – according to industry analysts.

STENOCARE has entered Germany with a …

GERMANY: STENOCARE is expanding outside Denmark with more prescription-based products.

Germany is the largest market in Europe with approx. 230.000 patients (out of 87 mill citizens) and projected sales of Euro 1 billion in 2027 – according to industry analysts.

STENOCARE has entered Germany with a THC10/CBD10 medical cannabis oil product together with an local experienced pharma partner.

CEO of Stenocare, Thomas Skovlund Schnegelsberg comments: “We have prepared for our German entry for a long time. Now we are ready to ship the first medical cannabis oil products to German patients with our local partner. This is a huge milestone for the company. Germany has grown significantly since the legalization in 2017, and it feels like jumping onto a train in full motion. We are humbled by its size and momentum, but we have a solid strategy to help us onboard and to enjoy the ride.”

Read the full announcement here: 2392760.pdf (cision.com)

STENOCARE is investing in new innovative medical cannabis products. Future patented protected products.

Since 2019, STENOCARE has been investing and working to develop the next generation of medical cannabis oil products. The company is partnering with both a pharmaceutical product development compa…

STENOCARE is investing in new innovative medical cannabis products. Future patented protected products.

Since 2019, STENOCARE has been investing and working to develop the next generation of medical cannabis oil products. The company is partnering with both a pharmaceutical product development company in Denmark and an experienced contract manufacturer in Canada to create innovative products that can potentially revolutionize the medical cannabis industry.

STENOCARE is one of the very few in the medical cannabis industry that has completed pharmacokinetic studies to test and document the effects of the new products. A study from 2022 tested the uptake of cannabinoids in the blood and found that the patented oil technology significantly increases the bioavailability of cannabinoids in the body. Read the announcement here. : STENOCARE

STENOCARE is hoping to have the first product ready for regulatory approval by the end of 2024.